Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
No dose adjustments occurred during the observation period, and no significant adverse events were reported (e.g., hypersensitivity reactions, hyperphosphatemia, kidney stones).Patients’ baseline characteristicsVariablesXLH (n = 27)GeneralAge (years)42 ± 13Female sex, n (%)13 (48)Weight (Kg)60 (55 to 78)Height (cm)150 (144 to 155)BMI (kg/m2)27 (25 to 32)XLH-related clinical dataPHEX mutation, n (%)23 (85)Family history of rickets, n (%)8 (30)Lower limb deformities and/or previous orthopedic surgery, n (%)25 (93)Fragility fractures/pseudofractures, n (%)19 (70)Enthesopathies, n (%)16 (59)Nephrolithiasis, n (%)9 (33)Dental abnormalities, n (%)16 (59)Laboratory testsSerum phosphate (mg/dL)1.5 (1.3 to 1.8)TmP/GFR (mg/dL)1.3 (0.9 to 1.5)Serum calcium (mg/dL)9.4 (9.0 to 9.6)Urinary calcium (mg/24 h)119 (82 to 148)25-OH-vitamin D (nmol/L)64 (49 to 89)Serum creatinine (mg/dL)0.65 (0.57 to 0.74)eGFR (ml/min/1.73 m2)115 (109 to 126)Data presented as mean ± SD or median and interquartile rangeBMI = body mass index, eGFR = estimated glomerular filtration rate, PHEX = phosphate regulating endopeptidase X-linked, TmP/GFR = tubular maximum phosphate reabsorption per glomerular filtration rate, XLH = X-linked hypophosphatemia
Source: Patients’ characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
None of the enrolled patients were members of the same family (i.e.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort
Study design awaiting verification · Journal of Endocrinological Investigation · 2025
Original publication title
Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
X-linked hypophosphatemia (XLH) is a genetic disorder characterized by elevated FGF23 levels, leading to phosphate wasting and hypophosphatemia, causing skeletal and extraskeletal abnormalities. Burosumab, an antibody targeting FGF23, improves hypophosphatemia and clinical outcomes. This study evaluated the real-world efficacy of burosumab and identify predictors of treatment response.
Source: PurposeAbstract: What methods does the paper describe?
Twenty-seven adult XLH patients (mean age 42 years; 48% female) from an Italian multicenter cohort were treated with burosumab for up to 24 weeks. Laboratory tests were evaluated at midpoints and endpoints (14 and 28 days) of the dosing interval. In a subset of patients (N = 11) followed for 48 weeks, laboratory tests and patient-reported outcomes were also assessed.
Source: MethodsAbstract: Results
After initiating burosumab, median serum phosphate levels increased from 1.5 mg/dL (IQR 1.3 to 1.8) to 2.0 mg/dL (IQR 1.7 to 2.4) (p < 0.05), remaining higher than baseline at the midpoints of the dosing interval for up to 24 weeks. Higher baseline phosphate predicted higher midpoint levels (p < 0.05), whereas higher baseline PTH (p < 0.05) and FGF23 (p < 0.001) were associated with lower phosphate levels at midpoints. In patients (N = 11) followed for 48 weeks, significant improvements in patient-reported outcomes in all patients were observed.
Both WOMAC Pain (r = 0.94, p = 0.02) and BPI Worst Pain (r = 0.98, p < 0.001) were positively correlated with increased phosphate at week 48.
Source: ResultsAbstract: Conclusion
Burosumab effectively increased serum phosphate levels and improved clinical outcomes in a real-world setting, particularly in patients with more substantial increases in serum phosphate levels. Baseline serum phosphate, PTH, and FGF23 levels predicted response, helping tailor treatment strategies and improve long-term patient management.
Source: ConclusionAuthors’ abstract
Purpose
X-linked hypophosphatemia (XLH) is a genetic disorder characterized by elevated FGF23 levels, leading to phosphate wasting and hypophosphatemia, causing skeletal and extraskeletal abnormalities. Burosumab, an antibody targeting FGF23, improves hypophosphatemia and clinical outcomes. This study evaluated the real-world efficacy of burosumab and identify predictors of treatment response.
Methods
Twenty-seven adult XLH patients (mean age 42 years; 48% female) from an Italian multicenter cohort were treated with burosumab for up to 24 weeks. Laboratory tests were evaluated at midpoints and endpoints (14 and 28 days) of the dosing interval. In a subset of patients (N = 11) followed for 48 weeks, laboratory tests and patient-reported outcomes were also assessed.
Results
After initiating burosumab, median serum phosphate levels increased from 1.5 mg/dL (IQR 1.3 to 1.8) to 2.0 mg/dL (IQR 1.7 to 2.4) (p < 0.05), remaining higher than baseline at the midpoints of the dosing interval for up to 24 weeks. Higher baseline phosphate predicted higher midpoint levels (p < 0.05), whereas higher baseline PTH (p < 0.05) and FGF23 (p < 0.001) were associated with lower phosphate levels at midpoints. In patients (N = 11) followed for 48 weeks, significant improvements in patient-reported outcomes in all patients were observed.
Both WOMAC Pain (r = 0.94, p = 0.02) and BPI Worst Pain (r = 0.98, p < 0.001) were positively correlated with increased phosphate at week 48.
Conclusion
Burosumab effectively increased serum phosphate levels and improved clinical outcomes in a real-world setting, particularly in patients with more substantial increases in serum phosphate levels. Baseline serum phosphate, PTH, and FGF23 levels predicted response, helping tailor treatment strategies and improve long-term patient management.
Supplementary Information
The online version contains supplementary material available at 10.1007/s40618-025-02596-3.
Publication and source details
Original title: Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort
Gaetano Paride Arcidiacono; Valentina Camozzi; Giovanni Tripepi; Cristina Eller-Vainicher; Giuseppe Vezzoli; Maria Luisa Brandi; Gemma Marcucci; Giuseppe Girasole; Antonio Aversa; Corrado Vitale; Gaetana Cerbone; Maria Michela D’Alessandro; Martina Zaninotto; Maria Fusaro; Marco Onofrio Torres; Michele Cannito; Alberta Cecchinato; Martin Diogo; Mor Peleg Falb; Francesca Guidolin; Marta Zampogna; Mario Plebani; Elena Campello; Paolo Simioni; Stefania Sella; Sandro Giannini
Journal of Endocrinological Investigation · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di PadovaOpen access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:22:44.689305+00:00
DOI: 10.1007/s40618-025-02596-3 · PMC12313718